The American Journal of Managed Care9h
Navigating Racial Disparities in Psoriatic Arthritis: Insights from Patient-Reported Outcomes
Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...
Managed Healthcare Executive13h
FDA Approves Imuldose, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
HealthDay on MSN17h
Health Tip: Keep Psoriatic Arthritis Fatigue in Check
Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...
HealthDay on MSN17h
Health Tip: Do You Have Psoriatic Arthritis?
Psoriatic arthritis is an inflammatory joint condition that is associated with the chronic skin condition psoriasis. The Arthritis Foundation says common symptoms of psoriatic arthritis include: ...
중앙일보17h
Dong-A ST's biosimilar product Imuldosa approved for U.S. market
Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...
DWP Personal Independence Payments of up to £737 a month paid for these 87 muscle and joint problems
More than 1.1 million adults across Great Britain are receiving support through PIP for musculoskeletal conditions, according ...